[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wang Yusheng\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100571220",false,"NCT06717412","Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy","Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy: A Multicenter, Prospective, Randomized, Double-blind, Non-inferiority Clinical Trial","Inclusion Criteria:\n\n* Preterm infants with less than or equal to 2000 grams of birth weight or less than or equal to 32 weeks of gestational age\n* Bilateral type 1 ROP with one of the following retinal findings in each eye\n* Zone I, stage 1+, 2+, 3+\u002F- disease, or\n* Zone II, stage 2+, 3+, disease, or\n* A-ROP\n\nExclusion Criteria:\n\n* Preterm infants with stage 4 or 5 ROP in one or both eyes\n* Have received any previous surgical or nonsurgical treatment for ROP, including laser photocoagulation, anti-VEGF therapy, vitrectomy\n* Have been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this child's pregnancy)\n* Have used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever is longer\n* Have active ocular infection within 5 days before or on the day of first investigational treatment\n* Have a history of hypersensitivity (either the patient or the mother) to any of the investigational treatments or to drugs of similar chemical classes\n* Have any contraindication for intravitreal injection clearly stated in the instructions\n* Have any ocular structural abnormality that may affect efficacy assessments\n* Have a history of any other congenital or systemic conditions that are assessed by the investigator to have a significant risk of severe impact on visual function\n* Have any other medical conditions or clinically significant comorbidities or personal circumstances that are assessed by the investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments","ALL",{"count":17,"type":18},146,"ESTIMATED","INTERVENTIONAL",[21],"NA","Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)",[24],"Retinopathy of Prematurity (ROP)","RECRUITING","2025-04-01",{"date":28,"type":29},"2025-04-04","ACTUAL",{"date":31,"type":29},"2024-11-29",{"date":33,"type":18},"2026-12-31",{"name":35,"class":36},"Wang Yusheng","OTHER",3,""]